WebOct 13, 2024 · Officials with the FDA have granted Fast Track designation to GS030 (GenSight Biologics) for the treatment of retinitis pigmentosa (RP). According to GenSight, GS030 combines AAV2 -based gene therapy with optogenetics to treat RP. “The Fast Track designation granted by the FDA to GS030 highlights the significant unmet … WebOct 12, 2024 · GS030 combines a gene therapy (GS030-DP) administered via a single intravitreal injection with a wearable optronic visual stimulation device (GS030-MD). Eligible patients in the first three cohorts are those affected by end-stage non-syndromic RP with no light perception (NLP) or light perception (LP) levels of visual acuity.
GenSight Biologics Announces FDA Grant of Fast Track ... - BioSpace
WebApr 6, 2024 · GS030 was granted orphan drug designation in the United States and Europe. PIONEER is being conducted in three centers across the United Kingdom, France, and the United States. GenSight expects to complete enrollment in the first half of 2024. Early findings may be available and released in the second half of 2024, and preliminary … WebPartial vision was restored in a blind patient with retinitis pigmentosa (RP) treated with the light-activated gene therapy GS030 (GenSight Biologics) followed by light stimulation with engineered goggles. matt brady basketball coach
GenSight Biologics to Present Data on GS010 and GS030 at the …
WebSep 15, 2024 · About GS030 GS030 leverages GenSight Biololgics’ optogenetics technology platform, a novel approach to restore vision in blind patients using a combination of ocular gene therapy and tailored ... WebGENSIGHT BIOLOGICS Inc. 3 East 28th Street New York, NY 10016 USA WebOct 16, 2024 · Anne Douar, GS030 Project Director, GenSight Biologics Oral Presentation OR07 – Session S1b: Ocular and CNS Gene and Cell Therapy I Wednesday, October 18, 2024, 8:30 am-10:40 am herborn demonstration